Literature DB >> 16138341

Association between adverse pregnancy outcomes and maternal factor V G1691A (Leiden) and prothrombin G20210A genotypes in women with a history of recurrent idiopathic miscarriages.

Touhami Mahjoub1, Nabil Mtiraoui, Hala Tamim, Sondes Hizem, Ramzi R Finan, Brahim Nsiri, Wassim Y Almawi.   

Abstract

Thrombophilia was implicated in the development of pregnancy complications, including recurrent idiopathic pregnancy loss, and is aggravated in women who are carriers of factor V G1691A (FV Leiden) and prothrombin (PRT) G20210A single-nucleotide polymorphisms (SNPs). Previous studies examined the role of FV-Leiden and PRT G20210A in recurrent pregnancy loss with conflicting results. Here we examined the prevalence of FV Leiden and PRT G20210A SNPs, in 200 women with 3 or more consecutive early (n = 87), late (n = 41), or early-late (n = 72) recurrent pregnancy losses, and 200 age-matched fertile parous control women. APC resistance (APCR) was detected functionally (measuring the activated clotting time triggered by activated factor X in presence of a fixed amount of purified APC), and FV-Leiden and PRT G20210A genotypes were assessed by PCR. The frequency of the mutant FV (0.1400 vs. 0.0276; P < 0.001) but not PRT 20210 (0.0100 vs. 0.0225; P = 0.159) allele was higher in patients than controls, respectively. APC resistance with factor V Leiden was seen in 27% of patients compared to 11.5% of controls, while APC resistance without factor V Leiden was seen in 12.5% of patients compared to 9.5% of controls. Regression analysis demonstrated that the significant predictors for early abortion was FV Leiden; those for late abortion were oral contraceptive, APCR, and FV Leiden; and predictors for early-late abortions were oral contraceptives, obesity, FV Leiden, and smoking. APC resistance and FV Leiden, as well as combination of both, are common thrombotic defects seen in women with idiopathic recurrent pregnancy loss, thus testing for these is recommended in women who have experienced recurrent miscarriages. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16138341     DOI: 10.1002/ajh.20419

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  6 in total

1.  A Multiplex Allele Specific Polymerase Chain Reaction (MAS-PCR) for the Detection of Factor V Leiden and Prothrombin G20210A.

Authors:  Morteza Bagheri; Isa Abdi Rad
Journal:  Maedica (Buchar)       Date:  2011-01

2.  The significance of genetic polymorphisms of factor V Leiden and prothrombin in the preeclamptic Polish women.

Authors:  Agnieszka Seremak-Mrozikiewicz; Krzysztof Drews; Ewa Wender-Ozegowska; Przemyslaw M Mrozikiewicz
Journal:  J Thromb Thrombolysis       Date:  2010-07       Impact factor: 2.300

3.  Epidemiology of Prothrombin G20210A Mutation in the Mediterranean Region.

Authors:  Mehrez M Jadaon
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-11-28       Impact factor: 2.576

4.  Comparison of two preventive treatments for patients with recurrent miscarriages carrying a C677T methylenetetrahydrofolate reductase mutation: 5-year experience.

Authors:  Philippe Merviel; Rosalie Cabry; Emmanuelle Lourdel; Segolene Lanta; Carole Amant; Henri Copin; Moncef Benkhalifa
Journal:  J Int Med Res       Date:  2017-01-12       Impact factor: 1.671

Review 5.  Factor V Leiden 1691G > A mutation and the risk of recurrent pregnancy loss (RPL): systematic review and meta-analysis.

Authors:  Mohammad Masoud Eslami; Majid Khalili; Mina Soufizomorrod; Saeid Abroun; Bahman Razi
Journal:  Thromb J       Date:  2020-06-24

6.  Risk factors and role of low molecular weight heparin in obstetric complications among women with inherited thrombophilia - a cohort study.

Authors:  María Manuela Clavijo; Carolina Valeria Mahuad; María de Los Angeles Vicente Reparaz; María Florencia Aizpurua; Adriana Ventura; Claudia Erica Casali
Journal:  Hematol Transfus Cell Ther       Date:  2019-06-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.